Table 5.

Results from multivariable logistic regression analysis with outcome variables after 6 months of follow-up.

	Quiescent vs most severe, OR [95% CI]	p-value	Quiescent vs all other patients, OR [95% CI]	p-value	Most severe vs all other patients, OR [95% CI]	p-value
Disease progression, inflammatory [B1] to stricturing [B2]	0.09 [0.01–1.67]	0.107	0.18 [0.02–1.84]	0.148	1.33 [0.22–8.12]	0.761
Disease progression, inflammatory [B1] to penetrating [B3]	NA		NA		NA
Need for systemic corticosteroids	0.24 [0.11–0.52]	0.000*	0.29 [0.14–0.57]	0.000*	1.98 [1.16–3.35]	0.012*
Need for immunomodulators	0.90 [0.29–2.78]	0.858	0.84 [0.31–2.28]	0.731	0.76 [0.37–1.55]	0.445
Need for biologics	0.39 [0.03–5.14]	0.473	0.62 [0.06–7.00]	0.702	4.43 [0.66–29.7]	0.126
Need for hospitalisation	1.20 [0.53–2.76]	0.661	1.18 [0.59–2.37]	0.639	0.98 [0.53–1.78]	0.936
Need for surgery [excluding at baseline]	2.02 [0.59–6.94]	0.266	1.83 [0.66–5.07]	0.246	0.73 [0.28–1.89]	0.512

Adjusted for age, disease location/behaviour according to the Montreal classification, smoking, and surgery at diagnosis. Phenotype according to Montreal classification, disease behaviour defined as non-stricturing/non-penetrating [B1], stricturing [B2], or penetrating [B3].

OR, odds ratio; 95% CI, 95% confidence interval; NA, not applicable.

*p-value below 0.05.